Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GlaxoSmithKline India reports higher second-quarter profit on specialty medicine growth
06:23am, Thursday, 06'th Nov 2025
India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for its specialty medicine portfolio.
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
04:15pm, Tuesday, 04'th Nov 2025
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis o
3 Dividend Stocks for November 2025
11:40am, Tuesday, 04'th Nov 2025
This month's trio includes two ADRs.
GSK's shares stuck in the middle lane
09:17am, Tuesday, 04'th Nov 2025
GSK PLC's (LSE:GSK, NYSE:GSK) latest quarter looked strong enough on pape, but the share price barely moved. The drugmaker has spent much of the past decade trapped between £15 and £18, and Deutsc
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of “Hold” by Analysts
01:46am, Monday, 03'rd Nov 2025
Shares of GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) have received an average recommendation of "Hold" from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. On
Aviva, GSK, Rolls and bitcoin miners: UK investors most trades shares in October
10:23am, Friday, 31'st Oct 2025
Retail investors on two UK platforms poured into a mix of large financials, big tech and crypto-related names and resource security plays in October, according to the latest trading data. On AJ Bell,
GSK delivers one of its cleaner beats, says leading bank
08:46am, Thursday, 30'th Oct 2025
After Wednesday's results, GSK PLC (LSE:GSK, NYSE:GSK) looks to have delivered one of its cleaner beats in recent quarters. Third-quarter numbers were comfortably ahead of expectations, with sales up
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
12:50pm, Wednesday, 29'th Oct 2025
GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.
GSK plc (GSK) Q3 2025 Earnings Call Transcript
12:46pm, Wednesday, 29'th Oct 2025
GSK plc ( GSK ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Emma Walmsley - CEO & Director Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO of ViiV Healthcare
GSK raises its sights after strong quarter and upgraded outlook
10:21am, Wednesday, 29'th Oct 2025
GSK PLC's (LSE:GSK, NYSE:GSK) third-quarter results offered the kind of clean beat investors like to see. Sales came in 4% ahead of UBS forecasts, with operating profit up 12% and strength visible ac
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026
09:08am, Wednesday, 29'th Oct 2025
British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported upbeat third-quarter results and upgraded its full-year 2025 guidance.
GSK Jumps After Hiked 2025 Guidance Widely Outperforms Expectations
08:58am, Wednesday, 29'th Oct 2025
GSK stock rose early Wednesday on strong 2025 guidance on the back of its third-quarter sales and earnings beat.
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
08:06am, Wednesday, 29'th Oct 2025
GSK (GSK) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.27 per share a year ago.
GSK lifts profit outlook after strong quarter and upbeat broker reaction
04:46am, Wednesday, 29'th Oct 2025
GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% to 1,707p after the pharmaceutical group raised its full-year guidance and delivered quarterly results that topped forecasts across almost every metric. The
GSK Raises Guidance After Sales, Earnings Growth
04:08am, Wednesday, 29'th Oct 2025
The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.
